Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Gains from Sales and Divestitures: 2018-2025

Historic Gains from Sales and Divestitures for Fortress Biotech (FBIO) over the last 7 years, with Sep 2025 value amounting to $737,132.

  • Fortress Biotech's Gains from Sales and Divestitures rose 618.95% to $737,132 in Q3 2025 from the same period last year, while for Sep 2025 it was $737,132, marking a year-over-year increase of 618.95%. This contributed to the annual value of $137,655 for FY2024, which is 24.30% down from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's Gains from Sales and Divestitures is $737,132, which was up 383.10% from $152,585 recorded in Q2 2025.
  • Fortress Biotech's Gains from Sales and Divestitures' 5-year high stood at $1.8 million during Q4 2022, with a 5-year trough of $17,206 in Q1 2024.
  • Over the past 3 years, Fortress Biotech's median Gains from Sales and Divestitures value was $137,655 (recorded in 2024), while the average stood at $199,889.
  • Per our database at Business Quant, Fortress Biotech's Gains from Sales and Divestitures tumbled by 94.35% in 2024 and then skyrocketed by 618.95% in 2025.
  • Over the past 5 years, Fortress Biotech's Gains from Sales and Divestitures (Quarterly) stood at $712,449 in 2021, then soared by 146.42% to $1.8 million in 2022, then slumped by 89.64% to $181,831 in 2023, then dropped by 24.30% to $137,655 in 2024, then surged by 618.95% to $737,132 in 2025.
  • Its Gains from Sales and Divestitures stands at $737,132 for Q3 2025, versus $152,585 for Q2 2025 and $77,124 for Q1 2025.